Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
December 07 2017 - 4:05PM
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company
committed to the discovery and development of engineered human
enzyme therapeutics for patients with rare genetic diseases and
cancer, today announced that it will provide a corporate update at
the upcoming BMO Capital Markets Prescription for Success
Healthcare Conference in New York on Thursday, December 14 at 8:30
a.m. ET.
To access the live and archived webcast of the presentation,
please visit the Investor Relations section of
the Aeglea BioTherapeutics website. The webcast and
presentation will be archived for viewing for 60 days
thereafter.
About Aeglea BioTherapeutics Aeglea is a
biotechnology company committed to developing enzyme-based
therapeutics in the field of amino acid metabolism to treat rare
genetic diseases and cancer. The company’s engineered human enzymes
are designed to modulate the extremes of amino acid metabolism in
the blood to reduce toxic levels of amino acids in inborn errors of
metabolism or target tumor metabolism for cancer treatment.
Pegzilarginase (AEB1102), Aeglea’s lead product candidate, is
currently being studied in two ongoing Phase 1 clinical trials in
patients with advanced solid tumors and acute myeloid
leukemia/myelodysplastic syndrome (AML/MDS). An additional study of
pegzilarginase combined with Merck’s pembrolizumab is expected to
initiate in early 2018. Additionally, Aeglea is recruiting patients
into its ongoing Phase 1/2 trial of pegzilarginase for the
treatment of patients with Arginase 1 Deficiency. The company is
building a pipeline of additional product candidates targeting key
amino acids.
For more information, please
visit http://aegleabio.com.
Media Contact: Kelly Boothe, Ph.D.
Pure Communications 415.946.1076 media@aegleabio.com
Investor Contact:Charles N. York II Chief
Financial Officer Aeglea BioTherapeutics
investors@aegleabio.com
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Sep 2023 to Sep 2024